| Today's Big NewsJun 5, 2023 |
|
Montgomery County, MD, is a thriving innovation hub for the life sciences industry. Be Next and learn how companies are making their mark in the immunology capital next to the nation’s capital. Learn more. 
|
|
| By Max Bayer Gilead and Arcus posted updated data at ASCO on all patients in a phase 2 trial testing the two companies' anti-TIGIT antibody. The combination of the TIGIT with an anti-PD-1 antibody was founded to reduce the risk of disease progression by 33% compared to the anti-PD-1 alone. |
|
|
|
| San Diego, CA |  |
|
|
By Annalee Armstrong Servier promised that interim data from a phase 3 study would “shift the treatment paradigm” for a type of brain cancer that has long been stagnant in clinical research in March. Now, we’ve got the goods. |
By James Waldron Easing pain may have been one of the original goals of medicine, but the zeitgeist has long since moved on to harder-to-treat conditions. That makes Eli Lilly’s efforts to reinvigorate the space all the more intriguing. |
By Annalee Armstrong Biogen and partner biotech Denali Therapeutics are trimming down a Parkinson’s disease clinical program that was not expected to complete until 2031 in hopes of getting some actionable data sooner. |
By Nick Paul Taylor Akero Therapeutics has gathered early evidence that its nonalcoholic steatohepatitis candidate plays nicely with GLP-1 receptor agonists. The phase 2b trial data suggest adding efruxifermin to a GLP-1 drug drives deep drops in liver fat without causing safety problems. |
By Nick Paul Taylor Affimed is rethinking development of its bispecific innate cell engager after getting a look at phase 1/2a monotherapy data. The biotech saw two partial responses in 15 patients, resulting in data that fell short of the continuation criteria but offered enough encouragement for it to plot more combination work. |
By James Waldron Foghorn Therapeutics has been sitting in dock for over a year due to an FDA clinical hold placed on its blood cancer drug in the wake of a patient death. Now, the biotech can set sail once again. |
By Helen Floersh A new precision medicine initiative is doing a bit of pharmaceutical matchmaking to see if preclinical evidence for cancer drug combos holds up beyond the lab. |
By Max Bayer CERo Therapeutics is still months away from the clinic but in the meantime is taking a detour to Wall Street via a SPAC deal. |
By James Waldron Erytech Pharma has branded an activist investor’s effort to obstruct a long-planned merger with Pherecydes as evidence that the group is trying to “destabilize” the biotech. |
By Angus Liu After a recent data leak revealed a dramatic benefit for J&J and Legend’s Carvykti in earlier treatment of multiple myeloma, the pair has peeled back some even more stunning efficacy results that could further pressure Bristol Myers Squibb’s rival CAR-T therapy, Abecma. |
By Andrea Park “Our data show that an enormous and even alarming number of patients are not getting genomic profiling when they get diagnosed,” Kevin Keegan, general manager of Illumina's oncology business, said in an interview at ASCO. |
By Joseph Keenan Flatiron Health inked a multi-year deal with Lifebit, which uses AI to collect biomedical data, to advance research and development of treatments targeting cancer. |
By Kevin Dunleavy Six months after filing for bankruptcy, Clovis was hoping for a last gasp win for fading cancer drug Rubraca. But the FDA has rejected the company’s bid for approval of the PARP inhibitor as a first-line maintenance treatment for ovarian cancer patients who have responded to a round of chemotherapy. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the need to democratize access to medications like emergency contraception, plus Elizabeth Holmes, the state of Alzheimer's research, and the rest of the week's headlines. |
|
|---|
|
|
|
October 16-18, 2023 | Boston, MA Hear from leading experts as they share their experiences and insights covering drug development from the earliest stage of research to FDA approval. Save $500 when you Register before June 19th! 
|
|
Whitepaper Autoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
eBook See how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
Whitepaper This paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
